![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana (S.P.S., T.B.F., W.I.D., W.F.B.); Purdue University, School of Pharmacy and Pharmacal Sciences, Department of Pharmacy Practice, Indianapolis, Indiana (S.K.Q.); and University of Iowa, College of Pharmacy, Iowa City, Iowa (D.J.M.)
Carboxylesterases metabolize ester, thioester, carbamate, and amide compounds to more soluble acid, alcohol, and amine products. They belong to a multigene family with about 50% sequence identity between classes. CES1A1 and CES2 are the most studied human isoenzymes from class 1 and 2, respectively. In this study, we report the cloning and expression of a new human isoenzyme, CES3, that belongs to class 3. The purified recombinant CES3 protein has carboxylesterase activity. Carboxylesterases metabolize the carbamate prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11; irinotecan) to its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), a potent topoisomerase I inhibitor. CYP3A4 oxidizes CPT-11 to two major oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin (NPC). In this study, we investigate whether these oxidative metabolites, NPC and APC, can be metabolized to SN-38 by purified human carboxylesterases, CES1A1, CES2, and CES3. We find that CPT-11, APC, and NPC can all be metabolized by carboxylesterases to SN-38. CES2 has the highest catalytic activity of 0.012 min-1 µM-1 among the three carboxylesterases studied for hydrolysis of CPT-11. NPC was an equally good substrate of CES2 in comparison to CPT-11, with a catalytic efficiency of 0.005 min-1 µM-1. APC was a very poor substrate for all three isoenzymes, exhibiting a catalytic activity of 0.015 x 10-3 min-1 µM-1 for CES2. Catalytic efficiency of CES3 for CPT-11 hydrolysis was 20- to 2000-fold less than that of CES1A1 and CES2. The relative activity of the three isoenzymes was CES2 > CES1A1 >> CES3, for all three substrates.
This article has been cited by other articles:
|
|
 |
|
  H.-J. Zhu, D. I. Appel, Y. Jiang, and J. S. Markowitz Age- and Sex-Related Expression and Activity of Carboxylesterase 1 and 2 in Mouse and Human Liver Drug Metab. Dispos., September 1, 2009; 37(9): 1819 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Watanabe, T. Fukami, M. Nakajima, M. Takamiya, Y. Aoki, and T. Yokoi Human Arylacetamide Deacetylase Is a Principal Enzyme in Flutamide Hydrolysis Drug Metab. Dispos., July 1, 2009; 37(7): 1513 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takahashi, M. Katoh, T. Saitoh, M. Nakajima, and T. Yokoi Different Inhibitory Effects in Rat and Human Carboxylesterases Drug Metab. Dispos., May 1, 2009; 37(5): 956 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Williams, K. O. Jones, G. D. Ponsler, S. M. Lowery, E. J. Perkins, S. A. Wrighton, K. J. Ruterbories, M. Kazui, and N. A. Farid The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 Drug Metab. Dispos., July 1, 2008; 36(7): 1227 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jewell, C. Ackermann, N. A. Payne, G. Fate, R. Voorman, and F. M. Williams Specificity of Procaine and Ester Hydrolysis by Human, Minipig, and Rat Skin and Liver Drug Metab. Dispos., November 1, 2007; 35(11): 2015 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Schiel, S.-l. Green, W. I. Davis, P. C. Sanghani, W. F. Bosron, and S. P. Sanghani Expression and Characterization of a Human Carboxylesterase 2 Splice Variant J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 94 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, D. Shi, D. Yang, X. Song, and B. Yan Interleukin-6 Alters the Cellular Responsiveness to Clopidogrel, Irinotecan, and Oseltamivir by Suppressing the Expression of Carboxylesterases HCE1 and HCE2 Mol. Pharmacol., September 1, 2007; 72(3): 686 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Cote, S. Kirzin, A. Kramar, J.-F. Mosnier, M.-D. Diebold, I. Soubeyran, A.-S. Thirouard, J. Selves, P. Laurent-Puig, and M. Ychou UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan Clin. Cancer Res., June 1, 2007; 13(11): 3269 - 3275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Higa Searching for the Holy Grail of oncology Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2260 - 2262. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Landowski, P. L. Lorenzi, X. Song, and G. L. Amidon Nucleoside Ester Prodrug Substrate Specificity of Liver Carboxylesterase J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kubo, S.-R. Kim, K. Sai, Y. Saito, T. Nakajima, K. Matsumoto, H. Saito, K. Shirao, N. Yamamoto, H. Minami, et al. FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2) Drug Metab. Dispos., October 1, 2005; 33(10): 1482 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Quinney, S. P. Sanghani, W. I. Davis, T. D. Hurley, Z. Sun, D. J. Murry, and W. F. Bosron Hydrolysis of Capecitabine to 5'-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1011 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Sun, D. J. Murry, S. P. Sanghani, W. I. Davis, N. Y. Kedishvili, Q. Zou, T. D. Hurley, and W. F. Bosron Methylphenidate Is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1 J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 469 - 476. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
